Phathom Pharmaceuticals Inc Revenue Growth Rates (PHAT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Phathom Pharmaceuticals Inc   (NASDAQ: PHAT)
 

PHAT's Revenue Growth by Quarter and Year

Phathom Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PHAT/growth
https://api.csimarket.com/api/v1/companies/PHAT/fundamentals
https://api.csimarket.com/api/v1/companies/PHAT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PHAT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 84.72
2nd Quarter June 74.27
1st Quarter March 58.30
FY 217.29





PHAT Revenue third quarter 2026 Y/Y Growth Comment
Phathom Pharmaceuticals Inc reported Revenue surge of 71.16% year on year in the third quarter 2026, to $ 84.72 millions, this is lower than Phathom Pharmaceuticals Inc 's recent average Revenue surge of 938.54%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 41 other companies have achieved higher Revenue growth. While Phathom Pharmaceuticals Inc ' s Revenue jump of 71.16% ranks overall at the positon no. 302 in the third quarter 2026.


PHAT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 71.16 %
2nd Quarter June 88.03 %
1st Quarter March 104.42 %
FY   -

Financial Statements
Phathom Pharmaceuticals Inc 's third quarter 2026 Revenue $ 84.72 millions PHAT's Income Statement
Phathom Pharmaceuticals Inc 's third quarter 2025 Revenue $ 49.50 millions Quarterly PHAT's Income Statement


PHAT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 14.07 %
2nd Quarter June 27.39 %
1st Quarter March 1.25 %
FY (Year on Year)   -


Back to PHAT Growth rate Comparisons >> Back to PHAT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #81
Overall #302

Revenue Y/Y Growth Statistics
High Average Low
4249.56 % 938.54 % 88.02 %
(Sep 30 2025)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #81
Overall #302
Revenue Y/Y Growth Statistics
High Average Low
4249.56 % 938.54 % 88.02 %
(Sep 30 2025)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Phathom Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
283.05 % 77.3 % -3.86 %
(Jun 30 2024)  


PHAT's III. Quarter Q/Q Revenue Comment
Phathom Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue rise of 14.07% quarter on quarter, to $ 84.72 millions.

Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Phathom Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 398.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #88
Overall #398
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #88
Overall #398
Revenue Q/Q Growth Statistics
High Average Low
283.05 % 77.3 % -3.86 %
(Jun 30 2024)  


PHAT's III. Quarter Q/Q Revenue Comment
Phathom Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue rise of 14.07% quarter on quarter, to $ 84.72 millions.

Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Phathom Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 398.


Phathom Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 274.88
Y / Y Revenue Growth (TTM) 86.75 %
Year on Year Revenue Growth Overall Ranking # 47
Seqeuential Revenue Change (TTM) 14.69 %
Seq. Revenue Growth (TTM) Overall Ranking # 435


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Phathom Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 275 millions, company would post below average annual Revenue growth of 14.69% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Phathom Pharmaceuticals Inc 's Revenue growth from the 74.27% growth in Jun 30 2026.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 36 to 47.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 55
Healthcare Sector # 12
Overall # 47

Revenue TTM Y/Y Growth Statistics
High Average Low
460.3 %
 234.42 %
110.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 55
Sector # 107
S&P 500 # 435
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Phathom Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 275 millions, company would post below average annual Revenue growth of 110.16% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Phathom Pharmaceuticals Inc 's Revenue growth from the 74.27% growth in Jun 30 2026.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 36 to 47.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 55
Healthcare Sector # 12
Overall # 47

Revenue TTM Y/Y Growth Statistics
High Average Low
460.3 %
234.42 %
110.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 55
Sector # 107
S&P 500 # 435




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PHAT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions


About Phathom Pharmaceuticals Inc Revenue Growth Rates (PHAT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Phathom Pharmaceuticals Inc (CIK 1783183).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-436961
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Phathom Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.